Anthropic Acquires Biotech Startup Coefficient Bio in 400 Million Deal!
Anthropic has purchased the stealth biotech AI startup called Coefficient Bio in a 400 million stock deal, according to The Information and Eric Newcomer.Â
Covering TechCrunch and other industry sources, the deal was completed recently even though there is no official confirmation about the financial details about the deal, according to multiple reports.
Anthropic continues its push into healthcare and life sciences. It has announced the launch of a tool named, Claude for life Sciences, in the following October. This tool aims to help scientific researchers make discoveries.Â
Coefficient Bio is a relatively new startup that has been operating quietly. It was founded less than a year ago by researchers with experience in computational drug discovery. The company focuses on using artificial intelligence to improve biological research and make drug discovery faster and more efficient.
The startup had a small team of around 10 people, but its work attracted attention because of its ambitious goal: using AI to better understand biology and accelerate scientific breakthroughs. After the acquisition, the entire team is expected to join Anthropic’s healthcare and life sciences division.
This move is part of a larger strategy by Anthropic to expand into scientific research. The company has already shown interest in this space with initiatives like AI tools designed for life sciences. By acquiring Coefficient Bio, Anthropic is strengthening its ability to apply AI in areas such as drug discovery, genomics, and biomedical research.
Experts believe this deal reflects a growing trend where AI companies are investing heavily in biotech. The idea is simple: combining advanced AI models with biological data can speed up research, reduce costs, and lead to faster development of new treatments.
Interestingly, Coefficient Bio was backed by investors and had remained largely under the radar before this acquisition. Reports suggest that the company was working on advanced AI systems aimed at transforming how scientists study and understand biology.
While Anthropic and Coefficient Bio have not shared many details about their future plans, the deal clearly signals where the industry is heading. AI is no longer limited to chatbots or software tools, it is becoming a key driver in scientific innovation.
